HOOKIPA Pharma (HOOK) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

HOOK HOOKIPA Pharma

Watchlist

3.790
-0.070-1.81%

Close Oct 31 16:00 ET

3.790
0.0000.00%

Post 16:07 ET

37.50MMarket Cap-919P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
GlobeNewswireOct 31 09:17 ET
JMP Securities Maintains HOOKIPA Pharma(HOOK.US) With Buy Rating, Maintains Target Price $24
Moomoo NewsOct 30 15:31 ET · Ratings
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
BenzingaOct 30 08:08 ET
Express News | HOOKIPA Pharma Inc - Initial Safety and Efficacy Data From Iit Expected in 2026
ReutersOct 30 07:30 ET
HOOKIPA Pharma Doses First Patients With Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer
GlobeNewswireOct 30 07:30 ET
Express News | HOOKIPA Pharma Doses First Patients With Eseba-Vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer
ReutersOct 30 07:30 ET

Comments

Jaguar8

14 hours ago

NEWS

$HOOKIPA Pharma (HOOK.US)$
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
HOOKIPA Pharma (NASDAQ: HOOK) announced that updated Phase 2 data for eseba-vec (HB200) plus pembrolizumab in first-line recurrent/metastatic HPV16-positive head and neck cancer will be presented at SITC 2024. The presentation will be delivered as a late-breaking poster by Dr. Alan Ho, Chief of Head and Neck Oncology Service at Memorial Sloan Cancer Cent...

Trytosaveabit

Oct 30 06:32

Update

$HOOKIPA Pharma (HOOK.US)$ Reuters· 2 mins ago
HOOKIPA Pharma Doses First Patients With Eseba-Vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer

Trytosaveabit

Sep 24 06:48

Watching! Look at date/time!

$HOOKIPA Pharma (HOOK.US)$ HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
16 MINUTES AGO, 7:30 AM EDT
VIA GLOBENEWSWIRE
NEW YORK and VIENNA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced that the Company will present preclinical data related...